Cancer Care


A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition
Principal Investigator (?)
Study Number
This phase III trial is studying giving lestaurtinib together with combination chemotherapy
to see how well it works compared to combination chemotherapy alone in treating infants with
newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different
ways to stop the growth of stop cancer cells, either by killing the cells or by stopping
them from dividing. Lestaurtinib may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth. Giving more than one drug (combination chemotherapy)
together with lestaurtinib may kill more cancer cells.
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)


View more details from

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.